Blood & Lymphoreticular

Vitamin B12 and folate deficiency: workup and replacement

Clinical Overview and When to Suspect B12/Folate Deficiency

— MCV >100 fL on routine CBC, especially >110 fL

— Unexplained fatigue, glossitis, pallor in an older adult

— Subacute combined degeneration: symmetric paresthesias, loss of vibration/proprioception, ataxia, spastic weakness, +Romberg

— Cognitive change, depression, or "reversible dementia" in elderly

— Patients on metformin ≥4 years, PPIs/H2 blockers chronically, or nitrous oxide abuse (oxidizes cobalt, inactivates B12)

— Post-gastric bypass, ileal resection (terminal ileum absorbs B12-IF complex), Crohn disease, tropical sprue, celiac disease

— Strict vegans (B12 absent from plant foods); folate deficiency in alcohol use disorder, malnourished, pregnancy, hemodialysis, methotrexate/phenytoin/trimethoprim use

— Unexplained pancytopenia with elevated LDH and indirect bilirubin (mimics hemolysis → "ineffective erythropoiesis")

Board pearl: A normal MCV does not exclude B12 deficiency — coexisting iron deficiency or thalassemia can normalize the MCV. Always check B12 in unexplained neuropathy or dementia regardless of MCV.

Step 3 management: In any patient with macrocytosis + neurologic symptoms, start empiric parenteral B12 before folate, even while labs return — folate alone in true B12 deficiency precipitates worsening myelopathy.

Megaloblastic anemia = impaired DNA synthesis from B12 (cobalamin) or folate deficiency → ineffective erythropoiesis, macrocytosis, hypersegmented neutrophils, pancytopenia in severe cases.

B12 deficiency is the higher-stakes diagnosis on Step 3 because it causes irreversible neurologic injury if untreated; folate deficiency does not (but folate repletion can mask B12-related anemia while neuropathy progresses).

When to suspect:

Pernicious anemia (autoimmune destruction of gastric parietal cells → loss of intrinsic factor) is the classic cause of B12 deficiency in older adults; associates with type 1 DM, vitiligo, Hashimoto, Addison disease, and confers 3-fold risk of gastric adenocarcinoma/carcinoid.

Presentation Patterns and Key History

— Symmetric distal paresthesias (feet > hands), often the earliest symptom

— Dorsal column loss: ↓vibration, ↓proprioception, +Romberg, sensory ataxia, wide-based gait

— Lateral corticospinal involvement: spasticity, hyperreflexia, +Babinski (combined upper + lower motor neuron signs without sensory level)

— Cognitive: memory loss, irritability, psychosis ("megaloblastic madness"), depression

— Autonomic: orthostasis, impotence, bladder dysfunction

— Diet: vegan/vegetarian duration, alcohol use, food insecurity

— Medications: metformin, PPIs (omeprazole >2 yrs), H2 blockers, methotrexate, trimethoprim, phenytoin, sulfasalazine, cholestyramine, nitrous oxide exposure (dental workers, recreational "whippets")

— Surgical: bariatric Roux-en-Y, gastrectomy, ileal resection, bowel resections for Crohn

— Autoimmune: thyroid disease, T1DM, vitiligo (→ pernicious anemia)

— Obstetric: pregnancy, lactation, recurrent miscarriage (folate)

— Family history of pernicious anemia or autoimmune disease

Key distinction: Folate deficiency causes identical hematologic findings but no neurologic disease. Any patient with neuro signs + macrocytosis is B12 until proven otherwise.

Board pearl: A vegan infant breastfed by a vegan mother is the classic pediatric stem — developmental regression, hypotonia, megaloblastic anemia.

Hematologic prodrome: insidious fatigue, exertional dyspnea, pallor, palpitations — often present for months because of slow body stores (B12 stores last ~3–5 years; folate stores only ~3–4 months).

Mucocutaneous: glossitis (smooth, beefy-red tongue — "Hunter glossitis"), angular cheilitis, mild jaundice (hemolysis from ineffective erythropoiesis), early greying of hair in pernicious anemia.

Neurologic (B12 only — folate causes NO neuro disease):

GI: anorexia, weight loss, early satiety, diarrhea (especially in tropical sprue/celiac).

Key history to elicit on Step 3:

Physical Exam Findings

— Glossitis: tongue smooth, atrophic papillae, beefy red, painful

— Angular stomatitis, pale mucous membranes

— Early greying of hair (classic pernicious anemia clue)

— Vibration (128 Hz tuning fork) at great toe and medial malleolus — earliest objective finding

— Proprioception at great toe (joint position sense)

— Romberg test — positive (sways/falls with eyes closed) indicates dorsal column dysfunction

— Gait — wide-based, sensory ataxic; tandem gait impaired

— Reflexes — variable: hyperreflexia from corticospinal involvement, OR areflexia if severe peripheral neuropathy coexists

— Babinski — upgoing toes

— Lhermitte sign — electric shock down spine on neck flexion (dorsal column irritation)

— Mental status — MMSE/MoCA: attention, memory deficits

— Cranial nerves: optic atrophy (rare), reduced taste

Key distinction: Subacute combined degeneration affects dorsal columns + lateral corticospinal tracts simultaneously → both decreased vibration/proprioception AND hyperreflexia/Babinski. This dual pattern, without a sensory level, distinguishes it from cord compression and from isolated peripheral neuropathy (e.g., diabetic).

Step 3 management: Document a baseline neurologic exam before initiating B12 — improvement in vibratory sense at 1–3 months is your bedside marker of response. Persistent deficits beyond 6–12 months are usually permanent.

Board pearl: Pain and temperature are typically preserved (spinothalamic tracts spared) — sensory ataxia without pinprick loss is highly suggestive.

General: pallor (conjunctival, palmar creases), mild scleral icterus, tachycardia, flow murmur if severe anemia (Hgb <7).

HEENT/Mucosal:

Skin: lemon-yellow tint = pallor + mild jaundice from ineffective erythropoiesis (hallmark of severe B12 deficiency); vitiligo suggests autoimmune polyendocrine background.

Cardiopulmonary: resting tachycardia, wide pulse pressure, systolic flow murmur, signs of high-output failure in severe anemia (elderly).

Neurologic exam (B12) — perform systematically:

Diagnostic Workup — Initial Labs

— MCV typically >100, often >110 fL in pure megaloblastic anemia

— RDW elevated (anisocytosis)

— Leukopenia and thrombocytopenia in moderate-severe cases (pancytopenia mimics MDS or leukemia)

— Reticulocyte count inappropriately low for degree of anemia

— Macro-ovalocytes (oval, not round, macrocytes)

— Hypersegmented neutrophils (≥5 lobes in >5% of neutrophils, or any with ≥6 lobes) — highly specific, often the earliest smear finding

— Anisopoikilocytosis, occasional teardrop cells, Howell-Jolly bodies

— ↑LDH (often markedly, >1000)

— ↑indirect bilirubin

— ↓haptoglobin

— Negative Coombs test — distinguishes from autoimmune hemolytic anemia

— <200 pg/mL → deficient

— 200–300 pg/mL → borderline, confirm with MMA/homocysteine

— >300 pg/mL → usually rules out deficiency (but falsely normal in pregnancy, MPN, liver disease, nitrous abuse)

Board pearl: Hypersegmented neutrophils can persist for 2 weeks after starting therapy — useful retrospective clue if a patient was treated empirically before labs were drawn.

Step 3 management: Always send B12 AND folate together. Treating folate deficiency without checking B12 is a classic safety event — partial hematologic correction occurs while neurologic disease progresses.

Key distinction: Reticulocyte count is low in megaloblastic anemia (production problem); high in hemolysis (destruction). The LDH/bilirubin elevation in B12 deficiency reflects intramedullary hemolysis, not peripheral.

CBC with differential and peripheral smear is the foundational test.

Peripheral smear hallmarks:

Hemolysis labs (ineffective erythropoiesis pattern):

Serum B12 (cobalamin):

Serum folate — reflects recent intake; RBC folate is more reliable for tissue stores but rarely needed.

Always check TSH, CMP, iron studies, reticulocyte count to exclude mimics and coexisting deficiencies.

Diagnostic Workup — Confirmatory and Etiologic Studies

— B12 deficiency: ↑MMA AND ↑homocysteine (B12 is cofactor for methylmalonyl-CoA mutase AND methionine synthase)

— Folate deficiency: normal MMA, ↑homocysteine (folate only feeds methionine synthase)

— MMA is the most sensitive and specific test for true tissue B12 deficiency

— Caveat: MMA can rise with renal insufficiency and volume depletion

— Anti-intrinsic factor antibodies — ~50–70% sensitive, >95% specific for pernicious anemia (order first)

— Anti-parietal cell antibodies — more sensitive (~80%) but less specific

— Serum gastrin — markedly elevated in pernicious anemia (atrophic gastritis → loss of acid → compensatory gastrin)

— Schilling test — historical, no longer performed

— EGD with biopsy if pernicious anemia confirmed or gastric symptoms — screen for atrophic gastritis, gastric carcinoid, adenocarcinoma

Board pearl: Order MMA before committing to lifelong B12 therapy when serum B12 is equivocal — false-normal B12 levels are common in pregnancy, MPN, liver disease, and oral contraceptive use.

Step 3 management: Confirmed pernicious anemia → screen for autoimmune comorbidities (TSH, fasting glucose/HbA1c) and baseline EGD; surveillance EGD every 3–5 years is reasonable given gastric cancer risk.

Key distinction: Elevated homocysteine alone is nonspecific — also seen in renal disease, hypothyroidism, B6 deficiency, and MTHFR variants.

Methylmalonic acid (MMA) and homocysteine — metabolic confirmation when B12 is borderline (200–300) or clinical suspicion is high despite normal level:

Etiology workup for B12 deficiency (drives long-term management):

For folate deficiency: workup is largely historical (diet, alcohol, drugs, malabsorption). Consider tTG-IgA for celiac if malabsorption suspected.

Bone marrow biopsy — rarely needed; reserved when MDS or leukemia is in the differential (megaloblastic marrow shows hypercellularity with nuclear-cytoplasmic asynchrony, "giant" metamyelocytes).

Risk Stratification and Management Logic

— Severity of anemia (Hgb, hemodynamics)

— Presence of neurologic involvement (drives urgency and route)

— Etiology (reversible vs lifelong replacement)

— Mild (Hgb 10–12, asymptomatic, no neuro): outpatient oral therapy reasonable

— Moderate (Hgb 7–10, fatigue, mild paresthesias): outpatient, but start parenteral B12 if neuro signs

— Severe (Hgb <7, symptomatic, cardiac strain, pancytopenia, prominent neuro deficits, altered mental status): admit, parenteral therapy, cautious transfusion only if true cardiac decompensation

— Parenteral (IM cyanocobalamin): pernicious anemia, neuro symptoms, severe deficiency, malabsorption (post-bariatric, ileal disease), inability to take PO

— High-dose oral (1000–2000 mcg/day): dietary deficiency, mild deficiency without neuro signs, patient preference; ~1% absorbed passively even without intrinsic factor — adequate at high dose

— Sublingual and nasal forms exist but parenteral remains the boards default for pernicious anemia

CCS pearl: In a CCS case of severe megaloblastic anemia: admit → IV access → type & screen → labs (B12, folate, MMA, homocysteine, retic, LDH, bilirubin, TSH, iron studies, anti-IF Ab) → IM cyanocobalamin 1000 mcg → oral folate 1 mg → cardiac monitor → cautious transfusion only if symptomatic. Recheck CBC at 1 week.

Board pearl: Never give folate alone when B12 status is unknown — "folate masking" precipitates subacute combined degeneration.

Triage decision hinges on three axes:

Severity tiers:

Transfusion caution: Megaloblastic anemia is chronic; patients are euvolemic-to-volume-expanded. Aggressive transfusion → acute pulmonary edema/CHF. Transfuse slowly, 1 unit at a time, with diuretic; replacement vitamin works rapidly (reticulocytosis at 3–5 days).

Route selection for B12:

Folate: always oral (1–5 mg/day); IV folate not needed.

Pharmacotherapy — First-Line Replacement

— Loading IM: 1000 mcg IM daily × 1 week, then weekly × 4 weeks, then monthly for life (pernicious anemia, ileal disease, post-bariatric)

— Alternative loading: 1000 mcg IM every other day × 2 weeks, then monthly

— High-dose oral: 1000–2000 mcg PO daily — equivalent efficacy to IM in dietary deficiency and selected pernicious anemia patients; requires adherence

— Intranasal cyanocobalamin (500 mcg weekly) — niche use for maintenance in adherent patients

— Hydroxocobalamin has longer half-life; used in Europe; also antidote for cyanide poisoning

— Side effects: rare; hypokalemia during brisk erythropoiesis (monitor K+ during early replacement)

— 1–5 mg PO daily × 1–4 months until repletion confirmed

— Continue indefinitely if underlying cause persists (chronic hemolysis, dialysis, methotrexate use, malabsorption)

— In pregnancy: 0.4–0.8 mg/day preconception/prenatal; 4 mg/day if prior NTD-affected pregnancy

— Reticulocytosis by day 3–5, peaks day 7–10

— Hgb rises ~1 g/dL per week; normalizes by 6–8 weeks

— Hypokalemia may develop in first week (potassium drives into new RBCs) — supplement if <3.5

— MCV normalizes by 6–8 weeks

— Neurologic improvement begins weeks 1–4, continues over 6–12 months; deficits >12 months are likely permanent

Step 3 management: In suspected concomitant B12 + folate deficiency, give B12 first (or simultaneously), never folate alone.

Board pearl: If reticulocyte count fails to rise by day 7, reconsider diagnosis — coexisting iron deficiency, thalassemia, infection, or MDS may blunt response. Check iron studies; iron deficiency frequently emerges as marrow recovery consumes iron.

B12 (cyanocobalamin or hydroxocobalamin):

Folate (folic acid):

Expected response (key for boards):

Monitor on therapy: CBC at 1 week, 1 month, 3 months; B12 level not needed routinely after replacement starts.

Treatment of Underlying Etiology and Special Scenarios

CCS pearl: For a patient on chronic methotrexate for RA with macrocytosis, order folic acid 1 mg daily (reduces toxicity without compromising efficacy) — do not stop MTX reflexively.

Board pearl: Tapeworm Diphyllobothrium latum (raw freshwater fish in Scandinavia, Great Lakes) competitively consumes B12 — niche but classic stem.

Pernicious anemia: lifelong parenteral B12 (or high-dose oral with verified adherence). Screen for and treat coexisting autoimmune disease. Baseline EGD; surveillance per GI based on findings (atrophic gastritis, intestinal metaplasia).

Post-bariatric surgery (Roux-en-Y, sleeve): routine prophylaxis with B12 (1000 mcg PO daily or 1000 mcg IM monthly), folate, iron, vitamin D, calcium, multivitamin — lifelong. Annual labs.

Ileal resection / Crohn disease with terminal ileum involvement: parenteral B12 indefinitely; oral inadequate due to malabsorption.

Celiac disease / tropical sprue: gluten-free diet (or antibiotics for tropical sprue) + repletion; absorption typically recovers.

Metformin-associated B12 deficiency: prevalence rises with duration and dose. ADA recommends periodic B12 screening in long-term metformin users, especially with neuropathy or anemia. Don't stop metformin reflexively — supplement B12 (oral 1000 mcg/day often sufficient).

PPI/H2 blocker users: deprescribe if no clear indication; supplement if symptomatic deficiency.

Nitrous oxide toxicity (recreational whippets, dental occupational): may have normal serum B12 but elevated MMA/homocysteine and florid neuro signs. Stop exposure, give parenteral B12; methionine and methylcobalamin may help.

Alcohol use disorder: folate deficiency predominates; also thiamine and B6. Repletion of all B-vitamins; address alcohol use.

Hemodialysis patients: folate 1 mg/day standard supplementation (dialyzable).

Drug-induced folate deficiency: methotrexate (rescue with leucovorin/folinic acid, not folic acid, in oncology dosing; folic acid 1 mg/day suffices for low-dose rheumatologic MTX), trimethoprim, phenytoin, sulfasalazine.

Special Populations — Elderly and Renal/Hepatic Impairment

— Prevalence of B12 deficiency 10–15%, often subclinical

— Mechanisms: atrophic gastritis (food-cobalamin malabsorption), PPI/H2 use, metformin, decreased intake, pernicious anemia

— Symptoms attributed to "aging" — fatigue, falls (proprioceptive loss), cognitive decline, depression — should prompt routine B12 screening

— Reversible dementia workup includes B12, TSH, RPR, HIV, depression screen

— Lower threshold to treat borderline levels (200–300) with confirmatory MMA

— Oral high-dose B12 (1000–2000 mcg/day) preferred for adherence; IM if neuro deficits or adherence concerns

— Watch for transfusion-associated circulatory overload (TACO) — diastolic dysfunction common; transfuse slowly with furosemide

— MMA falsely elevated in CKD → less reliable; rely on B12 level + clinical context

— Homocysteine also elevated in CKD

— Dialysis patients lose folate → supplement 1 mg/day

— Avoid high-dose folate >5 mg/day chronically in CKD (limited benefit, may mask)

— Serum B12 may be falsely elevated (release from hepatocytes) → don't be reassured by normal level if clinical suspicion is high; check MMA

— Folate deficiency common in cirrhosis (poor intake, alcohol)

— Avoid hepatotoxic confounders; B-vitamin replacement is safe

Step 3 management: In an elderly patient with falls + neuropathy + MCV 102 + B12 of 240, the right answer is send MMA and homocysteine, not "B12 is normal, reassure." Treat empirically if MMA elevated or clinical picture compelling.

Board pearl: Hospitalized elderly with new pancytopenia and "MDS workup pending" — always rule out B12/folate first; treatable in days, avoids bone marrow biopsy.

Key distinction: Falsely normal B12 occurs in liver disease, MPNs (CML), pregnancy. Falsely low B12 occurs in pregnancy, OCPs, MM.

Elderly (≥65):

Renal impairment / dialysis:

Hepatic impairment:

Special Populations — Pregnancy, Pediatrics, and Vulnerable Groups

— Folate requirements double; deficiency → neural tube defects (anencephaly, spina bifida), preterm birth, IUGR

— Preconception folate 400–800 mcg/day for all reproductive-age women (USPSTF Grade A)

— 4 mg/day if prior NTD pregnancy, or on anti-epileptics (valproate, carbamazepine), starting at least 1 month before conception through first trimester

— Serum B12 physiologically decreases in pregnancy (hemodilution + transfer) — interpret cautiously; MMA more reliable

— B12 deficiency in pregnancy → may also contribute to NTDs; supplement vegan/post-bariatric mothers

— Vegan mothers → exclusively breastfed infants develop severe B12 deficiency by 4–6 months: hypotonia, failure to thrive, developmental regression, irritability, megaloblastic anemia

— Treatment: parenteral B12 to infant; supplement mother

— Congenital intrinsic factor deficiency, transcobalamin II deficiency, Imerslund-Gräsbeck (selective ileal B12 malabsorption) — rare but classic stems

— Strict vegan adolescents → screen and supplement

— Lifelong B12, folate, iron, calcium, vitamin D supplementation

— Pregnancy planning: optimize nutrition before conception; closer prenatal monitoring

— Valproate, carbamazepine, phenytoin, phenobarbital deplete folate → higher NTD risk; counsel on contraception and 4 mg folate if planning pregnancy

Board pearl: The pediatric stem of a breastfed infant of a vegan mother with developmental regression and macrocytic anemia = maternal-fetal B12 deficiency. Treat infant urgently with parenteral B12.

Step 3 management: A 28-year-old woman with epilepsy on valproate planning pregnancy → switch to safer agent (lamotrigine) if possible AND start 4 mg folic acid daily before conception.

Pregnancy:

Lactation and infants:

Pediatrics:

Bariatric patients (often reproductive age women):

Patients on antiepileptics:

Complications and Adverse Outcomes

— Severe symptomatic anemia → high-output heart failure, especially elderly

— Pancytopenia → infection risk, bleeding

— Misdiagnosis as MDS or acute leukemia → unnecessary bone marrow biopsy, chemotherapy delays

— Subacute combined degeneration — sensory ataxia, spasticity, falls; partial reversibility depends on duration before treatment (deficits >6–12 months often permanent)

— Peripheral neuropathy — symmetric, distal, painful or numb

— Optic atrophy — rare, causes painless visual loss

— Dementia / cognitive impairment — may partially reverse with treatment if caught early

— Psychosis ("megaloblastic madness")

— Autonomic dysfunction — orthostasis, bladder/bowel, sexual dysfunction

— Hyperhomocysteinemia → independent risk marker for atherothrombosis and VTE (though lowering homocysteine with vitamins has not reduced cardiovascular events in RCTs — don't supplement for CV prevention alone)

— Folate deficiency → NTDs, preterm birth, low birthweight, placental abruption

— 3-fold increased risk gastric adenocarcinoma

— Gastric carcinoid tumors (from hypergastrinemia driving ECL cell hyperplasia)

— Coexisting autoimmune disease (thyroid, T1DM, Addison, vitiligo)

— Hypokalemia within first 48 h–1 week of replacement (intracellular shift with new RBC production) — can cause arrhythmias; monitor and replete

— Iron deficiency unmasked as erythropoiesis resumes

— Volume overload from transfusion in chronically anemic patients

Board pearl: The exam loves to test "folate alone given to B12-deficient patient → worsened neuropathy." Always replace B12 first or together.

Step 3 management: Monitor potassium daily for the first week of B12 replacement in severe deficiency; supplement preemptively if K+ <4.0.

Hematologic:

Neurologic (B12-specific, often the highest-stakes complications):

Cardiovascular:

Obstetric:

Pernicious anemia–specific:

Treatment-related:

Diagnostic delay is itself the dominant adverse outcome — missed B12 deficiency → permanent neurologic disability.

When to Escalate Care

— Hgb <7 with symptoms (chest pain, dyspnea, syncope, ECG changes)

— Hemodynamic instability — tachycardia, hypotension, hypoxia

— Severe neurologic deficits — inability to ambulate, urinary retention, altered mental status

— Pancytopenia with infection or bleeding

— Inability to tolerate oral intake; severe malabsorption requiring IV repletion

— Concern for alternative diagnosis (MDS, leukemia) requiring bone marrow biopsy

— Acute pulmonary edema from cardiac decompensation or overzealous transfusion

— Hemodynamic collapse

— Severe arrhythmia from hypokalemia during replacement

— Status epilepticus or rapidly progressing encephalopathy (rare)

— Hematology: unclear diagnosis, suspected MDS, refractory response to replacement, atypical smear, suspected hemolytic process

— Gastroenterology: suspected pernicious anemia (EGD for atrophic gastritis surveillance, rule out gastric malignancy), suspected celiac/Crohn, post-bariatric malabsorption

— Neurology: rapidly progressive myelopathy, atypical features, persistent deficits despite replacement, consider MRI cord (T2 hyperintensity in dorsal columns — "inverted V sign" on axial)

— Nutrition / dietitian: dietary counseling, bariatric follow-up, alcohol use disorder

— Endocrinology: new-onset autoimmune polyendocrine syndrome features

CCS pearl: For severe symptomatic megaloblastic anemia: order continuous cardiac monitoring, telemetry, IV access × 2, type and crossmatch, daily CBC and BMP — anticipate hypokalemia and the rapid reticulocytosis that often makes transfusion unnecessary.

Step 3 management: Persistent neurologic deficits 1–3 months into replacement → MRI spine + neurology consult; consider alternative or coexisting diagnoses (copper deficiency, HIV myelopathy, compressive lesion, MS).

Admit / inpatient management indications:

ICU triage:

Consult services:

Transfusion threshold: Hgb <7 generally; <8 in active cardiac disease. Transfuse one unit at a time, slowly, with furosemide if elderly or volume-sensitive. Avoid in stable chronic anemia — vitamins correct rapidly.

Key Differentials — Same-Category (Macrocytic Anemias)

— B12 deficiency — neuro signs, low B12, ↑MMA, ↑homocysteine

— Folate deficiency — no neuro signs, low folate, normal MMA, ↑homocysteine

— Drug-induced: methotrexate, trimethoprim, pyrimethamine (DHFR inhibitors); hydroxyurea, azathioprine, 5-FU, zidovudine (purine/pyrimidine synthesis); phenytoin

— Inborn errors: orotic aciduria, Lesch-Nyhan

— Alcohol use (direct marrow toxicity) — most common cause of mild macrocytosis in adults

— Liver disease — round macrocytes, target cells, acanthocytes

— Hypothyroidism — check TSH in any unexplained macrocytosis

— Reticulocytosis (hemolysis, recovery from blood loss) — large young RBCs, polychromasia

— Myelodysplastic syndrome (MDS) — older adults, dysplastic features, ringed sideroblasts, cytopenias unresponsive to vitamins; bone marrow definitive

— Aplastic anemia — pancytopenia with hypocellular marrow

— Pregnancy — physiologic mild macrocytosis

— Smoking, COPD — mild

— Smear (hypersegmented neutrophils → megaloblastic)

— B12, folate, TSH, LFTs, reticulocyte count

— If all normal and persistent → bone marrow biopsy for MDS

Key distinction: MDS vs B12 deficiency — both cause pancytopenia and macrocytosis in elderly. MDS has dysplastic features on smear, no response to vitamin replacement, and characteristic marrow/cytogenetic findings (e.g., del(5q)). Always replete B12/folate first before labeling as MDS.

Board pearl: In a patient with macrocytosis, low retic count, normal B12/folate, normal TSH — alcohol use disorder is the most likely culprit. Ask about drinking; check GGT and MCV trend with abstinence.

Megaloblastic vs non-megaloblastic is the foundational split.

Megaloblastic macrocytic anemias (impaired DNA synthesis, hypersegmented neutrophils):

Non-megaloblastic macrocytic anemias (normal DNA synthesis, no hypersegmented neutrophils):

Hereditary: Diamond-Blackfan, Fanconi anemia (pediatric stems)

Key labs that triage macrocytic anemia:

Key Differentials — Other-Category Mimics

— Cervical/thoracic cord compression (disc, tumor, abscess) — sensory level, bowel/bladder, urgent MRI; B12 deficiency has no sensory level

— Multiple sclerosis — relapsing-remitting, optic neuritis, INO, MRI plaques, oligoclonal bands in CSF

— Tabes dorsalis (tertiary syphilis) — dorsal column loss, Argyll Robertson pupils, +RPR/FTA-ABS

— HIV myelopathy / vacuolar myelopathy — clinically indistinguishable; check HIV

— Copper deficiency (post-bariatric, excessive zinc supplementation, denture cream) — causes identical myeloneuropathy and even macrocytic anemia; check serum copper and ceruloplasmin when B12 replacement fails

— Vitamin E deficiency — spinocerebellar syndrome in fat malabsorption

— Diabetic peripheral neuropathy — distal sensory, no UMN signs, normal vibration usually preserved in mild cases

— Charcot-Marie-Tooth, hereditary neuropathies — chronic, family history, distal atrophy

— Heavy metal toxicity (lead, mercury, arsenic) — occupational/environmental history

— MDS (covered above)

— Acute leukemia — blasts on smear, marrow definitive

— Hemolytic anemia with brisk reticulocytosis — elevated retic count distinguishes

— Drug-induced cytopenias — medication review

— Iron deficiency, riboflavin (B2) deficiency, niacin (pellagra) — overlap with B12; check full panel

— Candidal glossitis — pseudomembranous, immunocompromised

Key distinction: Copper deficiency myeloneuropathy is the most commonly missed B12 mimic on boards — same neurologic syndrome, often in post-bariatric or excess zinc (denture adhesives, lozenges) patients. Check copper if neuro signs persist despite normal B12 or fail to improve with replacement.

Step 3 management: Neuro signs + normal B12 + post-bariatric history → order serum copper, ceruloplasmin, zinc before more exotic workup.

For the neurologic presentation of B12 deficiency, differentiate from:

For the cytopenia/macrocytosis presentation:

For glossitis:

Secondary Prevention and Long-Term Plan

— Lifelong B12 replacement: cyanocobalamin 1000 mcg IM monthly OR high-dose oral 1000–2000 mcg daily (if adherent)

— Annual CBC + B12 level + symptom review

— Baseline EGD; surveillance every 3–5 years given gastric cancer/carcinoid risk (individualized by GI based on initial pathology)

— Screen for autoimmune comorbidities annually: TSH, fasting glucose/HbA1c, vitamin D

— Lifelong multivitamin + B12 (1000 mcg PO daily or 1000 mcg IM monthly) + iron + calcium 1200–1500 mg + vitamin D + thiamine + folate

— Annual labs: CBC, iron studies, B12, folate, 25-OH vitamin D, PTH, calcium, zinc, copper

— Lifelong parenteral B12 (oral inadequate)

— Continue offending agent if clinically necessary; supplement B12 orally

— ADA: periodic B12 screening in long-term metformin users

— Counsel on fortified foods (cereals, nutritional yeast, plant milks) and 250–500 mcg/day oral B12 supplement

— Address underlying cause (alcohol, malnutrition, malabsorption, drugs)

— Reproductive-age women: 400–800 mcg/day folic acid (USPSTF Grade A)

— Chronic hemolysis (sickle cell, thalassemia, hereditary spherocytosis): 1 mg/day lifelong

Board pearl: USPSTF recommends folic acid 400–800 mcg/day for all women planning or capable of pregnancy — a Grade A recommendation and a frequent prevention question.

Step 3 management: At every primary care visit for a patient with pernicious anemia, confirm B12 adherence, screen for autoimmune symptoms (fatigue, weight changes, polyuria), and document annual labs.

Pernicious anemia / autoimmune gastritis:

Post-bariatric surgery:

Ileal disease / resection:

Medication-induced (metformin, PPI):

Dietary (vegans/vegetarians):

Folate deficiency:

Cardiovascular note: Despite hyperhomocysteinemia being a CV risk marker, routine B-vitamin supplementation for CVD prevention is NOT recommended — RCTs (HOPE-2, NORVIT) showed no benefit.

Follow-Up, Monitoring, and Counseling

— Day 3–5: reticulocyte count should rise (confirms diagnosis and response)

— Day 7: CBC + BMP (K+, watch hypokalemia); iron studies if not yet sent

— Week 4: Hgb up ~1 g/dL/week; MCV trending down

— Week 6–8: Hgb and MCV normalize; if not, reassess for coexisting iron deficiency, ongoing blood loss, or alternative diagnosis

— CBC + B12 level annually

— Symptom review: paresthesias, gait, cognition, fatigue

— TSH annually in pernicious anemia

— Adherence assessment for oral therapy; consider switching to IM if levels fall

— Document deficits at baseline, 1 month, 3 months, 6 months, 12 months

— Improvement usually plateaus by 6–12 months; physical therapy and fall prevention counseling for residual deficits

— Adherence: skipping monthly IM injections → relapse within 6–12 months given depleted stores

— Diet: B12 only from animal products (meat, fish, eggs, dairy) and fortified foods; vegans must supplement

— Folate-rich foods: leafy greens, legumes, citrus, fortified grains

— Alcohol cessation: critical for folate replenishment and marrow recovery

— Medication review: discuss PPI deprescribing if no clear indication

— Pregnancy planning: preconception folate, screen B12 in vegan/post-bariatric women

CCS pearl: Order a reticulocyte count on day 5–7 of treatment. If absent → wrong diagnosis or coexisting deficiency. The "missing brisk reticulocytosis" is a classic CCS feedback prompt.

Step 3 management: Patient on monthly B12 IM presents 3 years later with returning paresthesias — ask about adherence to injections before assuming new pathology. Often the answer is missed doses.

Acute repletion phase monitoring:

Long-term monitoring (lifelong replacement):

Neurologic follow-up:

Counseling points (high-yield for boards):

Vaccinations / preventive care: ensure age-appropriate; autoimmune comorbidities should not delay routine immunizations.

Ethical, Legal, and Patient Safety Considerations

— Giving folate to a B12-deficient patient corrects the anemia but allows neurologic disease to progress silently

— Always pair B12 testing with folate testing; treat B12 first or together

— Mandated by clinical practice guidelines; failure is a quality-of-care issue and a frequent root-cause analysis topic

— Permanent neurologic deficits from delayed B12 diagnosis are a recognized malpractice risk

— Document timely workup of unexplained neuropathy, cognitive change, or macrocytosis

— Pernicious anemia patients discharged after hospitalization: explicit medication reconciliation for monthly B12; communicate to PCP

— Bariatric patients lost to follow-up develop preventable deficiencies — patient safety priority

— IM vs oral B12: discuss efficacy data (comparable in non-malabsorptive disease), patient preference, cost, adherence, injection burden

— Patients may decline injections; high-dose oral is acceptable for many — document discussion

— A breastfed infant of a vegan mother with B12 deficiency raises questions about parental counseling and follow-up; not automatically a child-protection issue if family is engaged and supplementation is initiated. Failure to follow recommended supplementation despite counseling may escalate to social work involvement

— Mandatory reporting thresholds vary by state but center on demonstrable neglect, not dietary choice alone

— Alcohol use disorder–related folate deficiency: counsel privately; protect 42 CFR Part 2 confidentiality for substance use disorder records

— IM B12 requires clinic visits; oral is cheaper and equally effective in many — discuss insurance coverage and patient circumstances

Board pearl: A patient receiving folate for "anemia" who returns with progressive ataxia and paresthesias is a never event — preventable with proper baseline workup.

Step 3 management: In hospital discharge planning for pernicious anemia, the single most important safety task is ensuring the first outpatient B12 injection or oral dose is scheduled and communicated.

Folate-masking error — the canonical safety event:

Diagnostic delay and disability:

Transitions of care:

Informed consent and shared decision-making:

Pediatric/maternal welfare:

Confidentiality:

Cost and access:

High-Yield Associations and Rapid-Fire Facts

Board pearl: "Beefy red tongue + neuropathy + macrocytic anemia in an elderly woman with vitiligo" → pernicious anemia. Order anti-IF antibodies and start IM B12.

B12 absorbed in terminal ileum (bound to intrinsic factor from gastric parietal cells); folate absorbed in proximal jejunum.

Body stores: B12 lasts 3–5 years (deficiency develops slowly); folate lasts 3–4 months (deficiency develops quickly).

B12 cofactor reactions: (1) methylmalonyl-CoA mutase (MMA → succinyl-CoA); (2) methionine synthase (homocysteine → methionine).

Folate trap hypothesis: B12 deficiency traps folate as methyl-THF, functionally creating folate deficiency at the DNA level.

Pernicious anemia associations: Hashimoto, Graves, T1DM, Addison disease, vitiligo, premature ovarian failure (autoimmune polyendocrine syndrome type II).

Schilling test: historical, no longer used; replaced by anti-IF antibodies and MMA.

Hypersegmented neutrophils ≥5 lobes — earliest and most specific smear finding.

Drugs that cause folate deficiency: Methotrexate, Trimethoprim, Phenytoin, Sulfasalazine, Pyrimethamine, Phenobarbital. ("MTP-SPP")

Drugs that cause B12 deficiency: Metformin (>4 years), PPIs/H2 blockers, colchicine, cholestyramine, nitrous oxide.

Diphyllobothrium latum: fish tapeworm → B12 deficiency.

Imerslund-Gräsbeck syndrome: rare pediatric ileal B12 malabsorption with proteinuria.

Pernicious anemia → 3× gastric cancer risk and increased gastric carcinoid risk.

Subacute combined degeneration: dorsal columns + lateral corticospinal + peripheral nerves.

Nitrous oxide: oxidizes cobalt in B12 → inactivates; "whippet abuse" with normal B12 levels but elevated MMA.

Pregnancy folate: 400–800 mcg/day; 4 mg/day if prior NTD or on antiepileptics.

MMA elevated → B12 deficiency; MMA normal, homocysteine elevated → folate deficiency.

K+ drop in first week of B12 replacement — monitor and replete.

Hgb rises ~1 g/dL/week; reticulocytosis by day 3–5.

Copper deficiency is the great mimic — post-bariatric, excess zinc, denture cream.

MRI spine in SCD: T2 hyperintensity in dorsal columns ("inverted V" or "rabbit ears" sign).

Board Question Stem Patterns

Board pearl: When stems show macrocytic anemia + autoimmune disease in an older adult, pernicious anemia is the answer until proven otherwise.

Step 3 management: Pattern recognition matters — match the cause to the route (IM for malabsorption/neurologic disease, oral for dietary), and always pair B12 testing with folate.

Stem 1 — Classic pernicious anemia: 68-year-old woman with vitiligo and hypothyroidism, 6 months of fatigue and tingling in feet. MCV 112, Hgb 9.5, LDH 800, indirect bili 1.8, smear with hypersegmented neutrophils. → Next step: B12, folate, MMA, anti-IF antibodies; treat with IM cyanocobalamin.

Stem 2 — Metformin user: 70-year-old man with T2DM on metformin 10 years, new paresthesias, MCV 104. → Check B12; supplement; do not stop metformin reflexively.

Stem 3 — Vegan infant: 8-month-old breastfed by vegan mother, developmental regression, hypotonia, megaloblastic anemia. → Maternal-fetal B12 deficiency; parenteral B12 to infant.

Stem 4 — Folate masking trap: Patient given folate for "macrocytic anemia," anemia improves but ataxia and paresthesias progress. → Missed B12; never give folate alone without checking B12.

Stem 5 — Post-bariatric neuropathy with normal B12: Roux-en-Y patient with myeloneuropathy, B12 normal. → Copper deficiency; check serum copper, ceruloplasmin, zinc.

Stem 6 — Nitrous abuse: Young dental worker or recreational whippet user with rapidly progressive ataxia, normal B12. → Check MMA/homocysteine; nitrous oxide–induced B12 inactivation.

Stem 7 — Pregnancy prevention: 26-year-old planning pregnancy on valproate for epilepsy. → 4 mg folic acid daily preconception; consider switching antiepileptic.

Stem 8 — Hypokalemia after replacement: Severe megaloblastic anemia, day 4 of B12, develops arrhythmia, K+ 2.8. → Anticipated intracellular shift; replete potassium.

Stem 9 — MDS vs B12: Elderly man with pancytopenia, MCV 108, dysplastic neutrophils. → Replete B12/folate first; if no response, bone marrow biopsy for MDS.

Stem 10 — Tapeworm: Patient from Great Lakes region eating raw freshwater fish, megaloblastic anemia. → Diphyllobothrium latum; praziquantel + B12.

Stem 11 — Borderline B12: B12 = 250, neuro symptoms. → Order MMA and homocysteine; treat if elevated.

One-Line Recap

Megaloblastic anemia is a clinical syndrome of impaired DNA synthesis from B12 or folate deficiency — distinguish them with MMA (elevated only in B12 deficiency), treat B12 deficiency promptly with parenteral or high-dose oral cobalamin (especially when neurologic signs are present), never give folate alone, and identify the underlying etiology to guide lifelong replacement strategy.

Board pearl: The single most important Step 3 takeaway is that early B12 replacement reverses neurologic disease — delay causes permanent disability, and folate must never be given alone when B12 status is unknown.

Recognize: macrocytosis + hypersegmented neutrophils + ineffective erythropoiesis (↑LDH, ↑indirect bili, ↓retic); add subacute combined degeneration features for B12.

Diagnose: serum B12 and folate; if B12 borderline (200–300), confirm with MMA (↑ in B12 deficiency) and homocysteine (↑ in both). Order anti-IF antibodies to confirm pernicious anemia. Always evaluate etiology: dietary, drugs (metformin, PPI, nitrous oxide, methotrexate, trimethoprim, phenytoin), malabsorption (post-bariatric, ileal Crohn, celiac), autoimmune (pernicious anemia).

Treat: IM cyanocobalamin 1000 mcg daily × 1 week → weekly × 4 → monthly for life for pernicious anemia/malabsorption/neurologic involvement; high-dose oral 1000–2000 mcg/day acceptable for dietary or non-malabsorptive cases. Folate 1–5 mg PO daily until repleted. Never folate alone. Monitor reticulocytosis at day 3–5 and potassium in week 1.

Prevent: preconception folic acid 400–800 mcg/day (4 mg if prior NTD/antiepileptics); lifelong B12 + multivitamin in post-bariatric patients; periodic B12 screening in long-term metformin users; EGD surveillance in pernicious anemia for gastric cancer/carcinoid.